MOATAZEDI DAVID sold $950K of EOLS

Evolus Inc (EOLS) reported Q3 2026 adjusted EBITDA of $1.2M, up $4.2M YoY. Global toxin revenue grew 11%, with Jeuveau gaining market share. HA business (Evolysse/Estyme) grew 40% in the quarter. The company added 500+ new accounts, reaching 19,000+ customers. Evolus expects three product launches by 2030. The FDA issued an untitled letter regarding a Jeuveau Instagram post, which was removed. Q4 operating expenses are expected to rise due to seasonality and a $1.5M option payment.

Evolus (EOLS) set a 2028 revenue target of $450M-$500M, reaffirming 2026 revenue guidance of $330M-$337M. CEO David Moatazedi highlighted four consecutive quarters of positive adjusted EBITDA and portfolio growth.

Evolus (EOLS) cut its full-year non-GAAP operating expense guidance to $210M-$213M and reaffirmed 2028 revenue targets of $450M-$500M with adjusted EBITDA margins of 13%-15%. The company expects FDA approval for Sculpt in Q4 2026 and a 2027 launch. Evolysse and Estyme gel lines are projected to contribute 10%-12% of full-year revenue. Evolus added over 500 purchasing accounts, bringing its total to over 19,000.

Evolus, Inc. (EOLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook • Global Net Revenue of $78.0 Million for the Third Quarter of 2026, an Incre

The FDA issued a warning to Evolus (NASDAQ:EOLS) for misleading Instagram promotions of its drug Jeuveau, citing exaggerated efficacy claims and downplayed risks. The agency found the posts misbranded the product and violated federal law. Evolus shares fell 5.92% to $7.23 on Friday, according to Benzinga Pro data.

The FDA criticized Evolus' (EOLS) Instagram ad for Jeuveau, calling it misleading. The company's stock fell 6.5%. The FDA objected to claims about the drug's effectiveness and risks. Evolus must respond within 15 days. Jeuveau is approved for treating frown lines and carries safety warnings.